Ultimately, understating MLCK/ROCK-associated AJC pathways will offer the opportunity to develop new pharmacological compounds with more selective actions on impaired intestinal barriers in patients with gastrointestinal disorders. The gene discussed is MYLK3; the disease is digestive system disorder.